Paediatric_JJ acute_JJ myeloid_NN leukaemia_NN with_IN the_DT t(_$ 7;12_CD )_-RRB- (_-LRB- q36;p13_NN )_-RRB- rearrangement_NN :_: a_DT review_NN of_IN the_DT biological_JJ and_CC clinical_JJ management_NN aspects_NNS
The_DT presence_NN of_IN chromosomal_JJ abnormalities_NNS is_VBZ one_CD of_IN the_DT most_RBS important_JJ criteria_NNS for_IN leukaemia_NN diagnosis_NN and_CC management_NN ._.
Infant_NN leukaemia_NN is_VBZ a_DT rare_JJ disease_NN that_WDT affects_VBZ children_NNS in_IN their_PRP$ first_JJ year_NN of_IN life_NN ._.
It_PRP has_VBZ been_VBN estimated_VBN that_IN approximately_RB one_CD third_NN of_IN infants_NNS with_IN acute_JJ myeloid_NN leukaemia_NN harbour_NN the_DT t(_$ 7;12_CD )_-RRB- (_-LRB- q36;p13_NN )_-RRB- rearrangement_NN in_IN their_PRP$ leukaemic_JJ blasts_NNS ._.
However_RB ,_, the_DT WHO_WDT classification_NN of_IN acute_JJ myeloid_NN leukaemia_NN does_VBZ not_RB yet_RB include_VB the_DT t(_$ 7;12_CD )_-RRB- as_IN a_DT separate_JJ entity_NN among_IN the_DT different_JJ genetic_JJ subtypes_NNS ,_, although_IN the_DT presence_NN of_IN this_DT chromosomal_JJ abnormality_NN has_VBZ been_VBN associated_VBN with_IN an_DT extremely_RB poor_JJ clinical_JJ outcome_NN ._.
Currently_RB ,_, there_EX is_VBZ no_DT consensus_NN treatment_NN for_IN t(_$ 7;12_CD )_-RRB- leukaemia_NN patients_NNS ._.
However_RB ,_, with_IN the_DT inferior_JJ outcome_NN with_IN the_DT standard_JJ induction_NN therapy_NN ,_, stem_NN cell_NN transplantation_NN may_MD offer_VB a_DT better_JJR chance_NN for_IN disease_NN control_NN ._.
A_DT better_JJR insight_NN into_IN the_DT chromosome_NN biology_NN of_IN this_DT entity_NN might_MD shed_VB some_DT light_NN into_IN the_DT pathogenic_JJ mechanisms_NNS arising_VBG from_IN this_DT chromosomal_JJ translocation_NN ,_, that_WDT at_IN present_NN are_VBP not_RB fully_RB understood_VBN ._.
Further_JJR work_NN is_VBZ needed_VBN to_TO improve_VB our_PRP$ understanding_NN of_IN the_DT molecular_NN and_CC genetic_JJ basis_NN of_IN this_DT disorder_NN ._.
This_DT will_MD hopefully_RB open_VB some_DT grounds_NNS for_IN possible_JJ tailored_VBN treatment_NN for_IN this_DT subset_NN of_IN very_RB young_JJ patients_NNS with_IN inferior_JJ disease_NN outcome_NN ._.
This_DT review_NN aims_VBZ at_IN highlighting_VBG the_DT cytogenetic_JJ features_NNS that_WDT characterise_VBP the_DT t(_$ 7;12_CD )_-RRB- leukaemias_VBZ for_IN a_DT better_JJR detection_NN of_IN the_DT abnormality_NN in_IN the_DT diagnostic_JJ setting_NN ._.
We_PRP also_RB review_VB treatment_NN and_CC clinical_JJ outcome_NN in_IN the_DT cases_NNS reported_VBN to_IN date_NN ._.
Keywords_NNS :_: Acute_JJ myeloid_NN leukaemia_NN ,_, Paediatric_JJ leukaemia_NN ,_, t(_SYM 7;12_CD )_-RRB- translocation_NN ,_, Chromosomal_JJ abnormalities_NNS ,_, HLXB9_NN gene_NN ,_, Clinical_JJ outcome_NN Introduction_NNP Leukaemia_NNP is_VBZ the_DT most_RBS common_JJ type_NN of_IN cancer_NN in_IN childhood_NN (_-LRB- Fig._NNP 1_CD )_-RRB- ._.
Among_IN acute_JJ leukaemias_NNS ,_, one_CD in_IN five_CD is_VBZ represented_VBN by_IN acute_JJ myeloid_NN leukaemia_NN (_-LRB- AML_NNP )_-RRB- ,_, whereas_IN four_CD fifths_NNS are_VBP acute_JJ lymphoblastic_JJ leukaemia_NN (_-LRB- ALL_DT )_-RRB- ._.
Cancer_NNP statistics_NNS from_IN the_DT National_NNP Registry_NNP of_IN Childhood_NNP Tumours_NNPS show_VBP a_DT peak_NN at_IN age_NN 2_CD -_SYM 3_CD years_NNS for_IN the_DT insurgence_NN of_IN ALL_DT ,_, whereas_IN AML_NNP is_VBZ more_RBR common_JJ within_IN the_DT first_JJ year_NN of_IN life_NN and_CC after_IN age_NN 10_CD ,_, with_IN an_DT incidence_NN of_IN 16_CD cases_NNS per_IN million_CD in_IN the_DT United_NNP Kingdom_NNP ._.
The_DT incidence_NN of_IN AML_NNP decreases_VBZ in_IN children_NNS older_JJR than_IN 2_CD years_NNS of_IN age_NN ,_, but_CC rises_VBZ in_IN adolescence_NN when_WRB it_PRP stays_VBZ stable_JJ until_IN adulthood_NN ,_, reaching_VBG its_PRP$ peak_NN in_IN older_JJR individuals_NNS [_-LRB- 1_CD ]_-RRB- ._.
Similar_JJ statistics_NNS have_VBP been_VBN encountered_VBN in_IN the_DT populations_NNS of_IN the_DT United_NNP States_NNPS [_-LRB- 2_CD ,_, 3_CD ]_-RRB- ._.
In_IN the_DT past_JJ three_CD decades_NNS ,_, there_EX has_VBZ been_VBN a_DT considerable_JJ improvement_NN in_IN the_DT cure_NN of_IN childhood_NN leukaemia_NN ,_, reaching_VBG a_DT long_JJ term_NN survival_NN rate_NN of_IN more_JJR than_IN 90_CD %_NN in_IN ALL_DT and_CC approximately_RB 70_CD %_NN in_IN AML_NNP [_-LRB- 3_CD ,_, 4_CD ]_-RRB- ._.
However_RB ,_, certain_JJ categories_NNS of_IN childhood_NN leukaemia_NN are_VBP still_RB considered_VBN high_JJ risk_NN ,_, and_CC this_DT level_NN of_IN risk_NN is_VBZ dictated_VBN by_IN the_DT presence_NN of_IN cytogenetic_JJ and_CC molecular_JJ genetic_JJ markers_NNS ._.
The_DT amended_VBN world_NN health_NN organization_NN (_-LRB- WHO_WP )_-RRB- leukaemia_NN classification_NN includes_VBZ the_DT most_RBS relevant_JJ chromosomal_JJ rearrangements_NNS to_TO allow_VB proper_JJ risk_NN stratification_NN of_IN leukaemia_NN patients_NNS [_-LRB- 5_CD ]_-RRB- ._.
To_IN date_NN ,_, the_DT t(_-LRB- 7;12_CD )_-RRB- (_-LRB- q36;p13_NN )_-RRB- rearrangement_NN found_VBN in_IN infant_NN AML_NNP has_VBZ not_RB been_VBN incorporated_VBN in_IN the_DT WHO_WDT classification_NN ,_, although_IN it_PRP has_VBZ been_VBN le_NN distributed_VBN under_IN the_DT terms_NNS of_IN the_DT Creative_NNP Commons_NNP Attribution_NNP License_NNP which_WDT permits_VBZ unrestricted_JJ use_NN ,_, distribution_NN ,_, and_CC reproduction_NN in_IN any_DT medium_NN ,_, associated_VBN with_IN poor_JJ clinical_JJ outcome_NN [_-LRB- 3_CD ,_, 6_CD ]_-RRB- ._.
Fig._NNP 1_CD Main_JJ types_NNS of_IN childhood_NN cancers_NNS ._.
The_DT ideogram_NN shows_VBZ the_DT different_JJ proportions_NNS of_IN cancers_NNS affecting_VBG paediatric_JJ patients_NNS ._.
Acute_JJ leukaemia_NN is_VBZ the_DT most_RBS commonly_RB reported_VBN cancer_NN in_IN children_NNS ,_, with_IN ALL_DT affecting_VBG approximately_RB 80_CD %_NN of_IN patients_NNS and_CC AML_NN diagnosed_VBN in_IN 15_CD -_SYM 20_CD %_NN of_IN patients_NNS ._.
Forms_NNS of_IN chronic_JJ leukaemia_NN and_CC myelodysplastic_NN syndromes_NNS are_VBP very_RB rare_JJ in_IN children_NNS and_CC their_PRP$ incidence_NN has_VBZ been_VBN omitted_VBN from_IN this_DT graph_NN (_-LRB- based_VBN on_IN cancers_NNS statistics_NNS collected_VBN from_IN the_DT National_NNP Registry_NNP of_IN Childhood_NNP Tumours_NNPS ,_, years_NNS 2009_CD -_SYM 2011_CD ,_, accessed_VBN through_IN the_DT Cancer_NNP Research_NNP UK_NNP website_NN )_-RRB-
This_DT cytogenetic_JJ entity_NN has_VBZ not_RB been_VBN associated_VBN with_IN a_DT particular_JJ morphologic_JJ or_CC immunophenotypic_JJ subtype_NN [_-LRB- 6_CD ,_, 7_CD ]_-RRB- ,_, but_CC has_VBZ been_VBN found_VBN in_IN a_DT range_NN of_IN AML_NN types_NNS as_RB well_RB as_IN a_DT case_NN of_IN myelodysplastic_JJ syndrome_NN [_-LRB- 8_CD ]_-RRB- ._.
The_DT scope_NN of_IN this_DT review_NN is_VBZ to_TO give_VB the_DT reader_NN a_DT comprehensive_JJ understanding_NN of_IN the_DT t(_$ 7;12_CD )_-RRB- rearrangement_NN at_IN the_DT chromosomal_JJ level_NN and_CC the_DT available_JJ methods_NNS for_IN the_DT detection_NN of_IN this_DT cytogenetic_JJ marker_NN for_IN an_DT improved_VBN diagnosis_NN and_CC a_DT better_JJR estimate_NN of_IN the_DT real_JJ incidence_NN of_IN this_DT type_NN of_IN leukaemia_NN ._.
We_PRP also_RB review_VB the_DT clinical_JJ outcome_NN and_CC the_DT therapeutic_JJ approaches_NNS that_WDT have_VBP been_VBN adopted_VBN in_IN the_DT cases_NNS reported_VBN to_IN date_NN ._.
Review_VB The_DT t(_NN 7;12_CD )_-RRB- rearrangement_NN :_: chromosomal_JJ appearance_NN and_CC cytogenetic_JJ features_NNS
The_DT t(_-LRB- 7;12_CD )_-RRB- rearrangement_NN typically_RB involves_VBZ the_DT long_JJ arm_NN of_IN chromosome_NN 7_CD at_IN band_NN q36_NN and_CC the_DT short_JJ arm_NN of_IN chromosome_NN 12_CD at_IN band_NN p13_NN (_-LRB- Fig._NNP 2_CD )_-RRB- ._.
These_DT chromosomal_JJ regions_NNS reside_VBP towards_IN the_DT end_NN of_IN the_DT chromosomes_NNS ,_, near_IN the_DT telomeres_NNS and_CC involve_VBP fragments_NNS of_IN similar_JJ sizes_NNS ._.
The_DT banding_NN patterns_NNS of_IN these_DT subtelomeric_JJ regions_NNS are_VBP typically_RB fairly_RB homogeneous_JJ and_CC not_RB distinctive_JJ of_IN a_DT specific_JJ chromosome_NN ._.
For_IN these_DT reasons_NNS the_DT t(_$ 7;12_CD )_-RRB- rearrangement_NN is_VBZ a_DT difficult_JJ cytogenetic_JJ entity_NN to_TO detect_VB microscopically_RB ,_, using_VBG conventional_JJ methods_NNS of_IN chromosome_NN banding_NN ._.
Nevertheless_RB ,_, early_JJ reports_NNS demonstrate_VBP identification_NN of_IN t(_SYM 7;12_CD )_-RRB- based_VBN on_IN banding_NN analysis_NN only_RB [_-LRB- 9_CD -_SYM 11_CD ]_-RRB- ._.
Furthermore_RB ,_, the_DT t(_NN 7;12_CD )_-RRB- has_VBZ been_VBN found_VBN associated_VBN with_IN deletions_NNS of_IN the_DT long_JJ arm_NN of_IN chromosome_NN 7_CD ,_, therefore_RB the_DT der_NNP (_-LRB- 7_CD )_-RRB- in_IN these_DT cases_NNS might_MD be_VB misinterpreted_VBN as_IN a_DT del_NNP (_-LRB- 7q_NNP )_-RRB- ._.
Fluorescence_NN in_IN situ_FW hybridisation_NN in_IN one_CD del_NNP (_-LRB- 7_CD )_-RRB- (_-LRB- q22_NN )_-RRB- case_NN ,_, helped_VBD revising_VBG this_DT abnormality_NN as_IN a_DT der_NNP (_-LRB- 7_CD )_-RRB- del_NNP (_-LRB- 7_CD )_-RRB- (_-LRB- q22q36_NNP )_-RRB- t(_-LRB- 7;12_CD )_-RRB- (_-LRB- q22;p13_NN )_-RRB- [_-LRB- 7_CD ,_, 8_CD ,_, 12_CD ]_-RRB- ._.
Translocation_NN breakpoints_NNS
In_IN the_DT t(_NN 7;12_CD )_-RRB- (_-LRB- q36;p13_NN )_-RRB- ,_, the_DT breakpoints_NNS on_IN chromosome_NN 12_CD are_VBP consistently_RB at_IN the_DT 5_CD â€²_NN end_NN of_IN ETV6_NNP ,_, between_IN exons_NNS 1_CD and_CC 3_CD ,_, whereas_IN the_DT breakpoints_NNS on_IN chromosome_NN 7_CD are_VBP quite_RB heterogeneous_JJ affecting_VBG band_NN q36_NNS in_IN regions_NNS proximal_JJ to_IN the_DT Homeobox_NNP HB9_NNP (_-LRB- HLXB9_NNP )_-RRB- gene_NN [_-LRB- 6_CD ,_, 12_CD ,_, 13_CD ]_-RRB- ,_, also_RB known_VBN as_IN MNX1_NNP (_-LRB- motor_NN neuron_NN and_CC pancreas_NN homeobox_NN 1_CD )_-RRB- ._.
There_EX have_VBP been_VBN descriptions_NNS of_IN breakpoints_NNS in_IN 7q31_CD [_-LRB- 10_CD ]_-RRB- ,_, 7q32_CD [_-LRB- 14_CD ,_, 15_CD ]_-RRB- ,_, and_CC 7q35_CD -_SYM 36_CD [_-LRB- 8_CD ]_-RRB- ._.
However_RB ,_, some_DT of_IN these_DT findings_NNS were_VBD not_RB validated_VBN using_VBG fluorescence_NN in_IN situ_FW hybridisation_NN (_-LRB- FISH_NNP )_-RRB- ._.
Informative_JJ FISH_NN probes_NNS spanning_VBG 7_CD q_NN would_MD have_VB been_VBN helpful_JJ towards_IN achieving_VBG a_DT more_RBR accurate_JJ definition_NN of_IN the_DT breakpoints_NNS in_IN these_DT cases_NNS ._.
Cryptic_JJ and_CC complex_JJ rearrangements_NNS
To_IN date_NN ,_, three_CD cases_NNS of_IN complex_JJ rearrangements_NNS harbouring_VBG the_DT t(_NN 7;12_CD )_-RRB- have_VBP been_VBN reported_VBN [_-LRB- 16_CD ,_, 17_CD ]_-RRB- ._.
These_DT three_CD way_NN translocations_NNS were_VBD characterised_VBN by_IN FISH_NNP and_CC described_VBN as_IN (_-LRB- i_CD )_-RRB- t(_-LRB- 5;7;12_CD )_-RRB- (_-LRB- q31;q36;p13_NN )_-RRB- [_-LRB- 16_CD ]_-RRB- ;_: (_-LRB- ii_CD )_-RRB- t(_-LRB- 1;7;12_CD )(_NN q25;q36;p13_NN )_-RRB- [_-LRB- 16_CD ]_-RRB- and_CC (_-LRB- iii_CD )_-RRB- t(_-LRB- 7;12;16_CD )_-RRB- (_-LRB- q36;p13_NN ;_: q12_NN )_-RRB- [_-LRB- 17_CD ]_-RRB- respectively_RB ._.
Due_IN to_IN the_DT breakpoints_NNS affecting_VBG the_DT terminal_JJ regions_NNS of_IN both_CC chromosomes_NNS 7_CD and_CC 12_CD ,_, the_DT t(_NN 7;12_CD )_-RRB- (_-LRB- q36;p13_NN )_-RRB- is_VBZ considered_VBN a_DT cryptic_JJ rearrangement_NN ._.
The_DT use_NN of_IN appropriate_JJ FISH_NN probes_NNS would_MD surely_RB improve_VB the_DT detection_NN of_IN this_DT abnormality_NN and_CC might_MD uncover_VB a_DT higher_JJR proportion_NN of_IN t(_$ 7;12_CD )_-RRB- translocations_NNS masked_VBN by_IN more_RBR complex_JJ rearrangements_NNS ,_, as_IN in_IN the_DT cases_NNS of_IN the_DT three_CD way_NN translocations_NNS previously_RB described_VBN ._.
Additional_JJ abnormalities_NNS Interestingly_RB ,_, the_DT majority_NN of_IN t(_$ 7;12_CD )_-RRB- cases_NNS have_VBP been_VBN reported_VBN in_IN association_NN with_IN specific_JJ aneusomies_NNS ._.
A_DT recent_JJ review_NN of_IN the_DT literature_NN reported_VBD that_IN only_RB 2_CD out_IN of_IN 44_CD cases_NNS harboured_VBD the_DT t(_NN 7;12_CD )_-RRB- as_IN a_DT sole_JJ abnormality_NN [_-LRB- 17_CD ]_-RRB- ._.
In_IN particular_JJ ,_, the_DT presence_NN of_IN one_CD or_CC more_RBR additional_JJ copies_NNS of_IN chromosomes_NNS 8_CD ,_, 19_CD and_CC /_SYM or_CC 22_CD have_VBP been_VBN recurrently_RB described_VBN [_-LRB- 6_CD ,_, 7_CD ,_, 15_CD ]_-RRB- ._.
Fig._NNP 2_CD Schematic_JJ representation_NN of_IN the_DT t(_$ 7;12_CD )_-RRB- (_-LRB- q36;p13_NN )_-RRB- and_CC fusion_NN transcript_NN formation_NN ._.
a_DT Representation_NN of_IN the_DT 7q36_CD and_CC 12p13_CD regions_NNS spanning_VBG 1_CD Mb_NN around_IN the_DT genes_NNS of_IN interests_NNS ._.
The_DT breakpoints_NNS are_VBP proximal_JJ to_IN the_DT HLXB9_NNP gene_NN on_IN chromosome_NN 7_CD and_CC at_IN the_DT 5_CD â€²_NN end_NN of_IN the_DT ETV6_NNP gene_NN on_IN chromosome_NN 12_CD ._.
HLXB9_NNP is_VBZ a_DT small_JJ gene_NN composed_VBN of_IN three_CD exons_NNS ._.
ETV6_NNP is_VBZ a_DT larger_JJR gene_NN composed_VBN of_IN eight_CD exons_NNS ._.
In_IN both_DT cases_NNS the_DT direction_NN of_IN transcription_NN is_VBZ from_IN the_DT telomeric_NN to_IN the_DT centromeric_JJ end_NN ._.
b_NNP
The_DT gene_NN location_NN and_CC direction_NN of_IN transcription_NN of_IN both_CC HLXB9_NNP and_CC ETV6_NNP are_VBP shown_VBN on_IN the_DT ideograms_NNS of_IN chromosomes_NNS 7_CD and_CC 12_CD ._.
For_IN each_DT gene_NN all_PDT the_DT exons_NNS are_VBP indicated_VBN ._.
c_NNP Derivative_JJ chromosomes_NNS 7_CD and_CC 12_CD :_: the_DT der_NNP (_-LRB- 12_CD )_-RRB- harbours_VBZ the_DT whole_JJ HLXB9_NN gene_NN and_CC the_DT 3â€²_JJ portion_NN of_IN ETV6_NNP including_VBG exons_NNS 3_CD -_SYM 8_CD ._.
If_IN a_DT fusion_NN transcript_NN arose_VBD from_IN this_DT translocation_NN ,_, splicing_NN of_IN HLXB9_NN exons_NNS 2_CD and_CC 3_CD as_RB well_RB as_IN any_DT genomic_JJ material_NN from_IN chromosome_NN 7_CD downstream_NN to_IN HLXB9_NN that_WDT was_VBD translocated_VBN on_IN the_DT der_NNP (_-LRB- 12_CD )_-RRB- should_MD take_VB place_NN
The_DT presence_NN of_IN these_DT additional_JJ abnormalities_NNS has_VBZ been_VBN reported_VBN in_IN samples_NNS at_IN diagnosis_NN and_CC /_, or_CC at_IN relapse_NN ,_, indicating_VBG that_IN the_DT acquired_VBN aneusomies_NN might_MD be_VB sign_NN of_IN clonal_JJ evolution_NN and_CC important_JJ for_IN the_DT establishment_NN and_CC the_DT survival_NN of_IN the_DT leukaemic_JJ clone_NN ._.
Molecular_NN mechanisms_NNS
Is_VBZ there_EX a_DT fusion_NN gene_NN ?_.
A_DT well_RB -_HYPH established_VBN driver_NN of_IN haematological_JJ malignancy_NN when_WRB a_DT chromosomal_JJ translocation_NN is_VBZ present_JJ ,_, is_VBZ the_DT formation_NN of_IN an_DT oncogenic_JJ fusion_NN gene_NN such_JJ as_IN BCRABL_NNP resulting_VBG from_IN the_DT t(_NN 9;22_CD )_-RRB- (_-LRB- q34_NN ;_: q11_NN )_-RRB- in_IN chronic_JJ myeloid_NN leukaemia_NN or_CC ETV6_NNP -_HYPH RUNX1_NNP in_IN t(_SYM 12;21_CD )_-RRB- (_-LRB- p13;q22_NN )_-RRB- positive_JJ ALL_DT [_-LRB- 18_CD ]_-RRB- ._.
As_IN a_DT consequence_NN of_IN these_DT gene_NN fusions_NNS ,_, a_DT fusion_NN transcript_NN is_VBZ produced_VBN with_IN subsequent_JJ generation_NN of_IN a_DT chimeric_JJ protein_NN whose_WP$ altered_VBN properties_NNS have_VBP an_DT impact_NN on_IN the_DT onset_NN of_IN the_DT disease_NN ._.
Reverse_JJ transcriptasepolymerase_NN chain_NN reaction_NN (_-LRB- RT_NNP -_HYPH PCR_NNP )_-RRB- to_TO identify_VB the_DT fusion_NN transcript_NN in_IN t(_SYM 7;12_CD )_-RRB- patients_NNS showed_VBD a_DT fusion_NN of_IN exon_NN 1_CD of_IN the_DT HLXB9_NNP gene_NN to_IN either_CC exons_NNS 2_CD or_CC 3_CD of_IN the_DT ETV6_NNP gene_NN resulting_VBG in_IN two_CD different_JJ HLXB9_NNP -_HYPH ETV6_NNP fusion_NN transcripts_NNS :_: an_DT out_IN of_IN frame_NN longer_JJR variant_NN (_-LRB- exon_NN 1_CD of_IN HLXB9_NNP to_IN exon_NNP Tosi_NNP et_NNP al_NNP ._.
Biomarker_NNP Research_NNP (_-LRB- 2015_CD )_-RRB- 3:21_CD Page_NN 4_CD of_IN 11_CD 2_CD of_IN ETV6_NNP )_-RRB- or_CC an_DT in_IN -_HYPH frame_NN shorter_JJR variant_NN (_-LRB- exon_NN 1_CD of_IN HLXB9_NNP to_IN exon_NN 3_CD of_IN ETV6_NNP )_-RRB- ,_, both_CC fusion_NN transcripts_NNS contain_VBP the_DT first_JJ exon_NN of_IN the_DT HLXB9_NN gene_NN as_RB well_RB as_IN the_DT ETS_NN domain_NN (_-LRB- DNA_NN and_CC protein_NN binding_NN domain_NN )_-RRB- and_CC the_DT pointed_VBN N_NN terminal_JJ domain_NN (_-LRB- PNT_NNP )_-RRB- (_-LRB- protein_NN -_HYPH protein_NN binding_NN domain_NN )_-RRB- of_IN the_DT ETV6_NNP gene_NN [_-LRB- 6_CD ,_, 19_CD -_SYM 21_CD ]_-RRB- ._.
However_RB ,_, the_DT presence_NN of_IN an_DT HLXB9_NNP -_HYPH ETV6_NNP fusion_NN transcript_NN has_VBZ been_VBN shown_VBN only_RB in_IN approximately_RB 50_CD -_SYM 60_CD %_NN of_IN t(_$ 7;12_CD )_-RRB- patients_NNS reported_VBN to_IN date_NN (_-LRB- Table_NNP 1_CD )_-RRB- ,_, whereas_IN the_DT reciprocal_JJ ETV6_NNP -_HYPH HLXB9_NNP transcript_NN has_VBZ never_RB been_VBN observed_VBN ._.
This_DT is_VBZ understandable_JJ when_WRB looking_VBG at_IN the_DT details_NNS of_IN the_DT translocation_NN breakpoints_NNS at_IN the_DT chromosomal_JJ /_, genomic_JJ level_NN ._.
Although_IN the_DT breakpoints_NNS on_IN chromosome_NN 12_CD are_VBP well_RB defined_VBN and_CC disrupt_VB the_DT ETV6_NNP gene_NN in_IN a_DT precise_JJ location_NN at_IN its_PRP$ 5_CD â€²_NN end_NN ,_, on_IN chromosome_NN 7_CD the_DT breakpoints_NNS are_VBP scattered_VBN in_IN different_JJ regions_NNS proximal_JJ to_IN the_DT HLXB9_NNP gene_NN ._.
This_DT implies_VBZ that_IN the_DT whole_JJ HLXB9_NN gene_NN is_VBZ transferred_VBN onto_IN the_DT der_NNP (_-LRB- 12_CD )_-RRB- ,_, but_CC there_EX is_VBZ no_DT disruption_NN of_IN the_DT gene_NN itself_PRP ._.
Moreover_RB ,_, between_IN HLXB9_NNP and_CC ETV6_NNP on_IN the_DT der_NNP (_-LRB- 12_CD )_-RRB- there_EX should_MD be_VB genomic_JJ material_NN of_IN variable_JJ extent_NN from_IN 7_CD q_NN ,_, depending_VBG on_IN the_DT location_NN of_IN the_DT 7_CD q_NN breakpoint_NN (_-LRB- Fig._NN 2_CD )_-RRB- ._.
This_DT means_VBZ that_IN an_DT HLXB9_NNP -_HYPH ETV6_NNP fusion_NN transcript_NN would_MD be_VB generated_VBN due_IN to_IN some_DT form_NN of_IN long_JJ range_NN splicing_NN ._.
Depending_VBG on_IN how_WRB efficient_JJ this_DT mechanism_NN is_VBZ ,_, the_DT fusion_NN transcript_NN might_MD fail_VB to_TO be_VB present_JJ in_IN all_DT t(_-LRB- 7;12_CD )_-RRB- patients_NNS ._.
Importantly_RB ,_, there_EX has_VBZ been_VBN no_DT report_NN on_IN the_DT presence_NN of_IN a_DT HLXB9_NNP -_HYPH ETV6_NNP protein_NN to_IN date_NN ,_, therefore_RB the_DT production_NN of_IN a_DT chimeric_JJ protein_NN as_IN an_DT oncogenic_JJ trigger_NN for_IN the_DT t(_$ 7;12_CD )_-RRB- leukaemias_NNS is_VBZ debatable_JJ ._.
HLXB9_VB over_IN -_HYPH expression_NN
As_IN a_DT fusion_NN transcript_NN is_VBZ detected_VBN in_IN only_RB approximately_RB fifty_CD per_NN cent_NN of_IN t(_$ 7;12_CD )_-RRB- AML_NN patients_NNS ,_, it_PRP is_VBZ debatable_JJ that_IN the_DT formation_NN of_IN the_DT fusion_NN gene_NN is_VBZ the_DT only_JJ contributor_NN to_IN leukaemogenesis_NN in_IN these_DT cases_NNS ._.
What_WP all_PDT the_DT t(_$ 7;12_CD )_-RRB- leukaemias_NNS have_VBP in_IN common_JJ is_VBZ the_DT over_JJ -_HYPH expression_NN of_IN the_DT Table_NNP 1_CD Proportion_NN of_IN patients_NNS showing_VBG an_DT HLXB9_NNP -_HYPH ETV6_NNP fusion_NN transcript_NN
No._NN of_IN t(_$ 7;12_CD )_-RRB- patients_NNS considered_VBN
No._NN of_IN patients_NNS with_IN HLXB9_NNP -_HYPH ETV6_NNP fusion_NN transcript_NN
Percentage_NN of_IN patients_NNS with_IN HLXB9_NNP -_HYPH ETV6_NNP fusion_NN transcript_NN
Reference_NN 2_CD 2_CD 100_CD [_-LRB- 21_CD ]_-RRB-
7_LS 4_CD 57_CD [_-LRB- 6_CD ]_-RRB-
2_LS 1_CD 50_CD [_-LRB- 13_CD ]_-RRB-
1_CD 1_CD 100_CD [_-LRB- 19_CD ]_-RRB-
7_LS 4_CD 57_CD [_-LRB- 20_CD ]_-RRB-
6_CD 6_CD 100_CD [_-LRB- 50_CD ]_-RRB-
Notes_NNS :_:
The_DT majority_NN of_IN patients_NNS considered_VBN in_IN this_DT table_NN were_VBD reported_VBN as_IN having_VBG the_DT t(_$ 7;12_CD )_-RRB- in_IN the_DT karyotype_NN of_IN their_PRP$ leukaemic_JJ cells_NNS ._.
However_RB ,_, in_IN 4_CD cases_NNS [_-LRB- 13_CD ,_, 50_CD ,_, 56_CD ]_-RRB- the_DT fusion_NN transcript_NN was_VBD described_VBN in_IN patients_NNS with_IN abnormalities_NNS of_IN 7q_NN and_CC or_CC 12_CD p_NN ,_, implying_VBG that_IN the_DT t(_NN 7;12_CD )_-RRB- might_MD have_VB been_VBN present_JJ ,_, but_CC underestimated_VBN in_IN these_DT cases_NNS HLXB9_IN gene_NN ,_, suggesting_VBG that_IN this_DT ,_, rather_RB than_IN the_DT formation_NN of_IN a_DT fusion_NN gene_NN ,_, might_MD be_VB the_DT driver_NN of_IN leukaemogenesis_NN in_IN these_DT patients_NNS ._.
Expression_NN of_IN other_JJ genes_NNS mapping_VBG at_IN 7q36_CD near_IN the_DT breakpoint_NN has_VBZ also_RB been_VBN evaluated_VBN and_CC quantified_VBN in_IN t(_$ 7;12_CD )_-RRB- patients_NNS ._.
However_RB ,_, this_DT analysis_NN showed_VBD that_DT expression_NN of_IN NOM1_NNP ,_, LMBR1_NNP and_CC RNF32_NNP in_IN 7q36_CD as_RB well_RB as_IN ETV6_NNP on_IN 12p13_CD was_VBD not_RB different_JJ from_IN that_DT observed_VBN in_IN AML_NNP patients_NNS without_IN the_DT t(_$ 7;12_CD )_-RRB- and_CC in_IN normal_JJ bone_NN marrow_NN [_-LRB- 6_CD ]_-RRB- ._.
The_DT expression_NN of_IN HLXB9_NN in_IN healthy_JJ progenitor_NN blood_NN cells_NNS in_IN the_DT bone_NN marrow_NN has_VBZ been_VBN investigated_VBN by_IN several_JJ groups_NNS ._.
Early_JJ expression_NN studies_NNS performed_VBD in_IN 1991_CD showed_VBD that_IN bone_NN marrow_NN enriched_VBN for_IN CD34_NN -_HYPH positive_JJ cells_NNS highly_RB expressed_VBD HLXB9_NNP ,_, whereas_IN unfractionated_JJ bone_NN marrow_NN cells_NNS expressed_VBD HLXB9_NN in_IN low_JJ levels_NNS ,_, and_CC bone_NN marrow_NN cells_NNS depleted_VBN of_IN CD34_NN -_HYPH positive_JJ cells_NNS did_VBD not_RB show_VB detectable_JJ levels_NNS of_IN HLXB9_NN [_-LRB- 22_CD ]_-RRB- ._.
Later_RBR on_RB ,_, the_DT same_JJ authors_NNS reported_VBD increased_VBN levels_NNS of_IN HLXB9_NN expression_NN in_IN acute_JJ leukaemias_NNS that_WDT were_VBD not_RB seen_VBN in_IN the_DT leukaemia_NN patients_NNS at_IN remission_NN ._.
These_DT studies_NNS suggested_VBD a_DT link_NN between_IN HLXB9_NNP over_IN -_HYPH expression_NN and_CC leukaemogenesis_NN [_-LRB- 23_CD ]_-RRB- ._.
Other_JJ authors_NNS reported_VBD a_DT relatively_RB low_JJ HLXB9_NN expression_NN in_IN normal_JJ bone_NN marrow_NN by_IN real_JJ time_NN quantitative_JJ PCR_NNP (_-LRB- RT_NNP -_HYPH Q_NNP -_HYPH PCR_NNP )_-RRB- and_CC did_VBD not_RB observe_VB HLXB9_NN expression_NN in_IN healthy_JJ CD34_NN -_HYPH positive_JJ bone_NN marrow_NN cells_NNS ,_, but_CC described_VBD increased_VBN levels_NNS in_IN the_DT bone_NN marrow_NN of_IN leukaemia_NN patients_NNS with_IN the_DT t(_$ 7;12_CD )_-RRB- rearrangement_NN [_-LRB- 6_CD ,_, 24_CD ]_-RRB- ._.
Observations_NNS from_IN our_PRP$ group_NN and_CC by_IN others_NNS confirmed_VBN elevated_VBN HLXB9_NNP expression_NN in_IN t(_SYM 7;12_CD )_-RRB- leukaemias_NNS as_RB well_RB as_IN in_IN some_DT patients_NNS with_IN acute_JJ myeloid_NN leukaemia_NN with_IN chromosomal_JJ abnormalities_NNS other_JJ than_IN the_DT t(_NN 7;12_CD )_-RRB- [_-LRB- 20_CD ,_, 25_CD ]_-RRB- ._.
HLXB9_NN expression_NN has_VBZ been_VBN associated_VBN with_IN hypo_NN -_HYPH methylation_NN of_IN its_PRP$ promoter_NN in_IN a_DT series_NN of_IN paediatric_JJ AMLs_NNS ._.
However_RB ,_, in_IN the_DT same_JJ study_NN it_PRP was_VBD found_VBN that_IN in_IN childhood_NN ALL_PDT the_DT HLXB9_NNP promoter_NN was_VBD hyper_JJ -_HYPH methylated_VBN leading_VBG to_IN down_IN -_HYPH regulation_NN of_IN this_DT gene_NN ._.
The_DT authors_NNS suggest_VBP that_IN HLXB9_NNP might_MD act_VB as_IN an_DT oncogene_NN in_IN AML_NNP ,_, whereas_IN it_PRP would_MD act_VB as_IN a_DT tumour_NN suppressor_NN gene_NN in_IN ALL_DT [_-LRB- 26_CD ]_-RRB- ._.
Over_IN -_HYPH expression_NN of_IN HLXB9_NNP has_VBZ been_VBN also_RB reported_VBN in_IN lymphoma_NN [_-LRB- 27_CD ,_, 28_CD ]_-RRB- and_CC cancer_NN types_NNS other_JJ than_IN haematological_JJ malignancies_NNS ,_, such_JJ as_IN breast_NN cancer_NN [_-LRB- 29_CD ]_-RRB- ,_, testicular_JJ cancer_NN [_-LRB- 30_CD ,_, 31_CD ]_-RRB- and_CC hepatocarcinoma_NN [_-LRB- 32_CD ]_-RRB- ._.
These_DT studies_NNS support_VBP the_DT idea_NN that_IN HLXB9_JJ involvement_NN might_MD be_VB pivotal_JJ in_IN other_JJ tumours_NNS as_RB well_RB as_IN leukaemia_NN ._.
Limited_JJ studies_NNS have_VBP been_VBN carried_VBN out_RP on_IN the_DT HLXB9_NNP expression_NN at_IN the_DT protein_NN level_NN ,_, whose_WP$ presence_NN has_VBZ been_VBN demonstrated_VBN in_IN bone_NN marrow_NN smear_NN of_IN leukaemia_NN patients_NNS with_IN the_DT t(_NN 7;12_CD )_-RRB- by_IN immunohistochemistry_NN [_-LRB- 16_CD ]_-RRB- ._.
Further_JJR studies_NNS on_IN leukaemia_NN as_RB well_RB as_IN other_JJ cancer_NN types_NNS are_VBP needed_VBN in_IN order_NN to_TO clarify_VB whether_IN the_DT presence_NN of_IN elevated_VBN HLXB9_NN transcript_NN corresponds_VBZ to_IN proportionate_JJ levels_NNS of_IN the_DT corresponding_VBG protein_NN ,_, or_CC whether_IN translation_NN is_VBZ regulated_VBN by_IN RNA_NNP interference_NN pathways_NNS [_-LRB- 31_CD ]_-RRB- ._.
HLXB9_NNP over_IN -_HYPH expression_NN and_CC genome_NN organisation_NN
An_DT increasing_VBG number_NN of_IN studies_NNS currently_RB focus_VBP on_IN gene_NN expression_NN in_IN the_DT context_NN of_IN the_DT three_CD dimensional_JJ (_-LRB- 3D_NN )_-RRB- genome_NN organisation_NN in_IN the_DT interphase_NN nucleus_NN [_-LRB- 33_CD ]_-RRB- ._.
Gene_NNP positioning_NN within_IN the_DT different_JJ areas_NNS of_IN the_DT cell_NN nucleus_NN has_VBZ been_VBN associated_VBN with_IN different_JJ levels_NNS of_IN gene_NN activity_NN ,_, with_IN the_DT general_JJ assumption_NN that_IN transcriptionally_RB active_JJ genes_NNS are_VBP localised_VBN in_IN the_DT nuclear_JJ interior_NN ,_, whereas_IN less_RBR active_JJ genes_NNS tend_VBP to_TO be_VB positioned_VBN towards_IN the_DT periphery_NN of_IN the_DT nucleus_NN [_-LRB- 34_CD -_SYM 37_CD ]_-RRB- ._.
It_PRP has_VBZ also_RB been_VBN shown_VBN that_IN gene_NN positioning_NN in_IN the_DT nucleus_NN is_VBZ not_RB fixed_VBN ,_, but_CC may_MD change_VB according_VBG to_IN different_JJ stages_NNS of_IN development_NN [_-LRB- 38_CD ,_, 39_CD ]_-RRB- and_CC in_IN pathologies_NNS [_-LRB- 40_CD ]_-RRB- ._.
It_PRP has_VBZ been_VBN demonstrated_VBN that_IN the_DT chromosome_NN 3D_NN structure_NN within_IN the_DT interphase_NN nucleus_NN has_VBZ an_DT influence_NN on_IN the_DT transcriptional_JJ activities_NNS of_IN specific_JJ Fig._NNP 3_CD Simplified_VBN model_NN of_IN radial_JJ chromosome_NN and_CC gene_NN organisation_NN in_IN th_NNP gene_NN dense_JJ and_CC gene_JJ poor_JJ bands_NNS are_VBP arranged_VBN in_IN a_DT zig_NN -_HYPH zag_NN manner_NN ,_, with_IN the_DT compact_JJ ,_, generally_RB not_RB -_HYPH transcribed_VBN ,_, chromatin_NN organisation_NN ._.
The_DT gene_NN dense_JJ r_VBZ open_JJ chromatin_NN structure_NN ,_, that_WDT favour_VBP gene_NN transcription_NN ._.
The_DT interaction_NN of_IN ci_NN regulatory_JJ factors_NNS consents_VBZ gene_NN activation_NN ._.
Upper_JJ right_NN :_: a_DT chromosomal_JJ transl_NN nucleus_NN could_MD determine_VB an_DT ectopic_JJ activation_NN of_IN translocated_VBN genes_NNS ,_, on_IN Bottom_JJ panel_NN :_: Schematic_JJ representation_NN of_IN the_DT distribution_NN of_IN FISH_NN signals_NNS rela_NN of_IN HLXB9_NN occupy_VBP a_DT peripheral_JJ positioning_NN ,_, whereas_IN both_DT copies_NNS of_IN ETV6_NNP are_VBP lo_FW HLXB9_NN gene_NN translocated_VBN on_IN the_DT der_NNP (_-LRB- 12_CD )_-RRB- is_VBZ repositioned_VBN towards_IN the_DT nuclear_NN in_IN the_DT der_NNP (_-LRB- 7_CD )_-RRB- is_VBZ repositioned_VBN towards_IN the_DT nuclear_JJ periphery_NN genes_NNS due_IN to_IN a_DT position_NN effect_NN mechanism_NN ._.
For_IN instance_NN ,_, gene_NN expression_NN at_IN a_DT specific_JJ locus_NN can_MD be_VB controlled_VBN in_IN cis_NN by_IN enhancer_NN elements_NNS localised_VBN at_IN a_DT distance_NN from_IN it_PRP ,_, via_IN formation_NN of_IN active_JJ chromatin_NN hubs_NNS (_-LRB- ACH_NNP )_-RRB- [_-LRB- 41_CD -_SYM 43_CD ]_-RRB- ._.
Several_JJ studies_NNS have_VBP been_VBN conducted_VBN to_TO observe_VB the_DT behaviour_NN of_IN cancer_NN loci_NNS in_IN the_DT interphase_NN nuclei_NNS using_VBG different_JJ cellular_JJ models_NNS and_CC some_DT authors_NNS proposed_VBD that_IN the_DT altered_VBN nuclear_JJ topography_NN of_IN genes_NNS could_MD be_VB used_VBN as_IN diagnostic_JJ tool_NN in_IN oncology_NN [_-LRB- 44_CD ,_, 45_CD ]_-RRB- ._.
Studies_NNS on_IN cancer_NN fusion_NN genes_NNS have_VBP shown_VBN nuclear_JJ repositioning_NN of_IN chromosomes_NNS and_CC genes_NNS after_IN a_DT translocation_NN event_NN [_-LRB- 46_CD -_SYM 48_CD ]_-RRB- and_CC this_DT repositioning_NN has_VBZ been_VBN shown_VBN to_TO have_VB an_DT impact_NN on_IN expression_NN profiling_NN [_-LRB- 49_CD ]_-RRB- ._.
We_PRP have_VBP observed_VBN the_DT behaviour_NN of_IN 7q_CD and_CC 12_CD p_NN loci_NNS in_IN the_DT interphase_NN nuclei_NNS of_IN leukaemia_NN cells_NNS carrying_VBG the_DT t(_$ 7;12_CD )_-RRB- in_IN a_DT number_NN of_IN patients_NNS and_CC shown_VBN that_IN the_DT e_NN cell_NN nuclei_NNS ._.
Upper_JJ left_VBN :_:
In_IN the_DT cell_NN nucleus_NN ,_, chromosomes_NNS composed_VBN of_IN gene_NN poor_JJ regions_NNS (_-LRB- blue_JJ segments_NNS )_-RRB- close_VBP to_IN the_DT nuclear_JJ envelope_NN ,_, in_IN a_DT egions_NNS (_-LRB- red_JJ segments_NNS )_-RRB- are_VBP located_VBN in_IN a_DT more_RBR internal_JJ position_NN ,_, with_IN an_DT s_NN -_HYPH acting_NN or_CC trans_JJ -_HYPH acting_NN sequences_NNS ,_, as_RB well_RB as_IN the_DT presence_NN of_IN specific_JJ ocation_NN that_WDT involves_VBZ regions_NNS normally_RB positioned_VBN in_IN different_JJ areas_NNS of_IN the_DT the_DT basis_NN of_IN the_DT new_JJ nuclear_JJ environment_NN where_WRB they_PRP are_VBP repositioned_VBN ._.
tive_VB to_IN the_DT regions_NNS involved_VBN in_IN the_DT t(_$ 7;12_CD )_-RRB- rearrangement_NN ._.
Left_VBN :_: Both_DT copies_NNS calised_VBN towards_IN the_DT interior_NN in_IN the_DT nucleus_NN of_IN normal_JJ cells_NNS ._.
Right_JJ :_:
The_DT terior_NN ,_, whereas_IN the_DT remaining_VBG portion_NN of_IN the_DT ETV6_NNP gene_NN translocated_VBD on_IN Tosi_NNP et_NNP al_NNP ._.
Biomarker_NNP Research_NNP (_-LRB- 2015_CD )_-RRB- 3:21_CD Page_NN 6_CD of_IN 11_CD translocation_NN leads_VBZ to_IN repositioning_NN of_IN the_DT loci_NNS of_IN interest_NN (_-LRB- Fig._NNP 3_CD )_-RRB- [_-LRB- 20_CD ]_-RRB- ._.
What_WP does_VBZ this_DT imply_VB in_IN terms_NNS of_IN gene_NN transcription_NN ?_.
We_PRP have_VBP shown_VBN the_DT presence_NN of_IN HLXB9_NN transcripts_NNS in_IN the_DT same_JJ samples_NNS with_IN the_DT t(_$ 7;12_CD )_-RRB- rearrangement_NN by_IN RT_NNP -_HYPH PCR_NNP ,_, however_RB ,_, we_PRP did_VBD not_RB investigate_VB the_DT origin_NN of_IN the_DT transcript_NN ._.
We_PRP assume_VBP that_IN the_DT nascent_JJ transcript_NN would_MD originate_VB from_IN the_DT der_NNP (_-LRB- 12_CD )_-RRB- ,_, due_IN to_IN the_DT juxtaposition_NN of_IN the_DT HLXB9_NNP gene_NN to_IN the_DT downstream_JJ region_NN of_IN ETV6_NNP ._.
This_DT would_MD facilitate_VB new_JJ interactions_NNS between_IN active_JJ cis_JJ elements_NNS and_CC the_DT HLXB9_NNP promoter_NN ,_, leading_VBG to_IN the_DT formation_NN of_IN active_JJ chromatin_NN hubs_NNS and_CC repositioning_NN of_IN the_DT chromatin_NN in_IN the_DT cell_NN nucleus_NN ._.
Alternatively_RB ,_, active_JJ trans_JJ sequences_NNS from_IN different_JJ chromosomes_NNS could_MD activate_VB HLXB9_NN by_IN a_DT bridge_NN formation_NN in_IN the_DT new_JJ nuclear_JJ environment_NN ._.
Gene_NNP expression_NN signature_NN of_IN t(_$ 7;12_CD )_-RRB- leukaemias_NNS and_CC HLXB9_NN targets_NNS
The_DT first_JJ study_NN to_TO investigate_VB expression_NN profiling_NN of_IN t(_SYM 7;12_CD )_-RRB- leukaemias_NNS was_VBD conducted_VBN by_IN Wildenhain_NNP et_NNP al_NNP ._. [_-LRB- 50_CD ]_-RRB- ,_, who_WP compared_VBD leukaemic_JJ blasts_NNS of_IN patients_NNS positive_JJ for_IN the_DT presence_NN of_IN the_DT HLXB9_NNP /_SYM ETV6_NNP fusion_NN transcript_NN with_IN those_DT with_IN MLL_NNP rearrangements_NNS ._.
It_PRP has_VBZ to_TO be_VB said_VBN that_IN these_DT represent_VBP the_DT two_CD most_RBS common_JJ chromosomal_JJ rearrangements_NNS found_VBN in_IN very_RB young_JJ AML_NN patients_NNS ,_, including_VBG infants_NNS and_CC mainly_RB children_NNS younger_JJR than_IN 2_CD years_NNS of_IN age_NN ._.
The_DT authors_NNS found_VBD that_IN genes_NNS expressed_VBN in_IN the_DT MLL_NNP group_NN of_IN patients_NNS ,_, were_VBD significantly_RB down_RB -_HYPH regulated_VBN in_IN the_DT HLXB9_NN /_, ETV6_NNP positive_JJ patients_NNS ._.
These_DT included_VBD HOX_NN genes_NNS and_CC genes_NNS characteristic_JJ for_IN the_DT MLL_NNP -_HYPH induced_VBN transformation_NN process_NN such_JJ as_IN MEIS1_NNP ,_, HOXA9_NNP and_CC C_NNP -_HYPH MYB_NNP ._.
On_IN the_DT other_JJ hand_NN ,_, together_RB with_IN over_IN -_HYPH expression_NN of_IN HLXB9_NNP ,_, the_DT HLXB9_NNP /_SYM ETV6_NNP positive_JJ patients_NNS showed_VBD up_RP -_HYPH regulation_NN of_IN genes_NNS implicated_VBN in_IN cell_NN -_HYPH cell_NN interactions_NNS and_CC cell_NN adhesion_NN such_JJ as_IN EDIL3_NNP ,_, CNTNAP5_NNP ,_, ANGPT1_NNP ,_, DSG2_NNP ,_, ITGA9_NNP ,_, ITGAV_NNP ,_, KDR_NNP and_CC SIGLEC6_NNP ._.
These_DT are_VBP known_VBN to_TO be_VB implicated_VBN in_IN the_DT maintenance_NN of_IN quiescent_JJ haematopoietic_JJ stem_NN cells_NNS (_-LRB- HSC_NNP )_-RRB- and_CC homeostasis_NN of_IN the_DT HSC_NN niche_NN ._.
Overall_RB ,_, this_DT study_NN implies_VBZ that_IN the_DT mechanisms_NNS of_IN leukaemogenesis_NN in_IN these_DT two_CD types_NNS of_IN childhood_NN leukaemia_NN are_VBP fundamentally_RB very_RB different_JJ ._.
Evidence_NN would_MD suggest_VB that_IN the_DT HLXB9_NN /_, ETV6_NNP positive_JJ leukaemias_NNS might_MD be_VB initiated_VBN through_IN an_DT alterations_NNS of_IN interactions_NNS between_IN the_DT HSC_NN and_CC the_DT HSC_NN niche_NN ._.
Balgobind_NNP et_FW al._FW [_-LRB- 51_CD ]_-RRB- used_VBD expression_NN microarrays_NNS to_TO examine_VB a_DT large_JJ cohort_NN of_IN samples_NNS from_IN paediatric_JJ patients_NNS with_IN AML_NNP including_VBG seven_CD samples_NNS from_IN patients_NNS with_IN the_DT t(_$ 7;12_CD )_-RRB- ._.
The_DT authors_NNS built_VBD a_DT classifier_NN based_VBN on_IN 59_CD genes_NNS that_WDT enabled_VBD them_PRP to_TO identify_VB very_RB specific_JJ expression_NN profiling_NN signatures_NNS predictive_JJ of_IN cytogenetic_JJ and_CC molecular_JJ subtypes_NNS ._.
This_DT classification_NN tool_NN ,_, based_VBN on_IN the_DT genetic_JJ heterogeneity_NN of_IN paediatric_JJ AML_NN ,_, is_VBZ of_IN great_JJ diagnostic_JJ potential_NN although_IN its_PRP$ feasibility_NN and_CC implementation_NN in_IN the_DT diagnostic_JJ setting_NN will_MD have_VB to_TO be_VB further_RB explored_VBN ._.
The_DT significance_NN and_CC the_DT impact_NN of_IN HLXB9_NN up_IN -_HYPH regulation_NN in_IN the_DT t(_$ 7;12_CD )_-RRB- leukaemias_NNS merits_VBZ further_JJ studies_NNS ._.
These_DT would_MD shed_VB some_DT light_NN on_IN the_DT pathways_NNS triggered_VBN by_IN this_DT chromosomal_JJ rearrangement_NN ._.
The_DT only_JJ report_NN to_IN date_NN to_TO explore_VB possible_JJ targets_NNS for_IN HB9_NNP (_-LRB- the_DT transcription_NN factor_NN coded_VBN by_IN the_DT HLXB9_NNP gene_NN )_-RRB- in_IN haematopoietic_JJ cells_NNS was_VBD performed_VBN on_IN the_DT HL_NNP -_HYPH 60_CD myeloid_NN cell_NN line_NN using_VBG ChiPon_NNP -_HYPH chip_NN and_CC expression_NN profiling_NN analyses_NNS [_-LRB- 24_CD ]_-RRB- ._.
This_DT study_NN describes_VBZ binding_NN of_IN HB9_NNP to_IN the_DT prostaglandin_JJ E_NNP receptor_NN 2_CD (_-LRB- PGTER2_NNP )_-RRB- promoter_NN resulting_VBG in_IN downregulation_NN of_IN PGTER2_NN and_CC consequent_JJ reduction_NN of_IN intracellular_JJ cAMP_NN level_NN ._.
This_DT down_IN -_HYPH regulatory_JJ effect_NN on_IN PGTER2_NNP expression_NN was_VBD also_RB observed_VBN in_IN t(_$ 7;12_CD )_-RRB- patients_NNS ._.
Together_RB with_IN repression_NN of_IN PGTER2_NNP ,_, Wildenhain_NNP et_FW al._FW [_-LRB- 24_CD ]_-RRB- ,_, found_VBD that_IN HLXB9_NNP expression_NN in_IN the_DT HL60_NNP cell_NN line_NN had_VBD mostly_RB a_DT down_IN -_HYPH regulatory_JJ effect_NN on_IN other_JJ genes_NNS ,_, particularly_RB ZYX_NNP and_CC ETS1_NNP ._.
Physiologically_RB ,_, expression_NN of_IN PGTER2_NNP modulates_VBZ differentiation_NN of_IN osteoclasts_NNS ._.
Upregulation_NNP of_IN PTGER2_NNP has_VBZ been_VBN shown_VBN in_IN immature_JJ myeloid_NN precursors_NNS ._.
PTGER2_NNP becomes_VBZ subsequently_RB down_RB -_HYPH regulated_VBN after_IN the_DT cells_NNS have_VBP differentiated_VBN into_IN osteoclasts_NNS [_-LRB- 52_CD ]_-RRB- ._.
Further_JJR work_NN is_VBZ needed_VBN to_TO clarify_VB the_DT implications_NNS of_IN PTGER2_NN down_IN -_HYPH regulation_NN on_IN the_DT bone_NN marrow_NN niche_NN and_CC on_IN the_DT differentiation_NN of_IN immature_JJ pre_NN -_HYPH leukaemic_JJ cells_NNS ._.
Diagnostic_JJ tools_NNS Chromosome_NNP banding_VBG The_DT t(_NN 7;12_CD )_-RRB- (_-LRB- q36;p13_NN )_-RRB- rearrangement_NN affects_VBZ the_DT subtelomeric_JJ regions_NNS of_IN chromosomes_NNS 7_CD and_CC 12_CD respectively_RB ._.
Due_IN to_IN the_DT small_JJ size_NN of_IN the_DT genomic_JJ fragments_NNS translocated_VBN ,_, this_DT rearrangement_NN is_VBZ difficult_JJ to_TO detect_VB using_VBG the_DT conventional_JJ methods_NNS of_IN chromosome_NN banding_NN ._.
Fluorescence_NN in_IN situ_FW hybridisation_NN Fluorescence_NNP in_IN situ_FW hybridisation_NN (_-LRB- FISH_NNP )_-RRB- has_VBZ been_VBN fundamental_JJ for_IN the_DT identification_NN of_IN the_DT t(_NN 7;12_CD )_-RRB- as_IN a_DT nonrandom_JJ rearrangement_NN [_-LRB- 7_CD ]_-RRB- ._.
Initially_RB ,_, probes_NNS covering_VBG the_DT entire_JJ ETV6_NNP gene_NN in_IN conjunction_NN with_IN 7q36_CD probes_NNS have_VBP been_VBN used_VBN for_IN the_DT screening_NN of_IN a_DT relatively_RB large_JJ number_NN of_IN paediatric_JJ patients_NNS ._.
This_DT screening_NN enabled_VBD us_PRP to_TO estimate_VB the_DT incidence_NN of_IN this_DT translocation_NN of_IN approximately_RB one_CD third_NN of_IN patients_NNS with_IN infant_NN leukaemia_NN [_-LRB- 7_CD ]_-RRB- ._.
It_PRP has_VBZ to_TO be_VB noted_VBN that_IN the_DT breakpoints_NNS on_IN 7q36_CD in_IN the_DT t(_NN 7;12_CD )_-RRB- patients_NNS were_VBD found_VBN to_TO be_VB heterogeneous_JJ and_CC generally_RB proximal_JJ to_IN HLXB9_NN without_IN disrupting_VBG the_DT gene_NN itself_PRP [_-LRB- 12_CD ]_-RRB- ._.
A_DT three_CD colour_NN FISH_NN assay_NN with_IN probes_NNS flanking_VBG the_DT HLXB9_NNP gene_NN was_VBD developed_VBN specifically_RB for_IN the_DT detection_NN of_IN the_DT t(_NN 7;12_CD )_-RRB- (_-LRB- q36;p13_NN )_-RRB- (_-LRB- Fig._NNP 4_CD )_-RRB- ._.
This_DT assay_NN enabled_VBD us_PRP to_TO successfully_RB identify_VB cryptic_JJ and_CC more_RBR complex_JJ t(_-LRB- 7;12_CD )_-RRB- rearrangements_NNS [_-LRB- 17_CD ]_-RRB- ._.
Commercially_RB available_JJ FISH_NN probes_NNS for_IN the_DT detection_NN of_IN the_DT t(_$ 12;21_CD )_-RRB- translocation_NN are_VBP also_RB suitable_JJ for_IN the_DT detection_NN of_IN the_DT t(_NN 7;12_CD )_-RRB- ,_, where_WRB a_DT split_VBN ETV6_NNP signal_NN is_VBZ found_VBN on_IN the_DT der_NNP (_-LRB- 7_CD )_-RRB- and_CC on_IN the_DT der_NNP (_-LRB- 12_CD )_-RRB- ._.
Fig._NNP 4_CD Fluorescence_NN in_IN situ_NN hybridisation_NN (_-LRB- FISH_NNP )_-RRB- performed_VBD on_IN metaphase_NN chromosomes_NNS harbouring_VBG the_DT t(_NN 7;12_CD )(_NN q36;p13_NN )_-RRB- ._.
a_DT FISH_NN using_VBG a_DT three_CD colour_NN approach_NN enables_VBZ the_DT detection_NN of_IN both_CC normal_JJ chromosomes_NNS 7_CD (_-LRB- harbouring_VBG only_RB blue_JJ hybridisation_NN signals_NNS )_-RRB- and_CC 12_CD (_-LRB- harbouring_VBG green_JJ and_CC orange_JJ fluorescent_JJ signals_NNS )_-RRB- and_CC their_PRP$ derivatives_NNS (_-LRB- green_JJ signals_NNS on_IN the_DT der_NN (_-LRB- 7_CD )_-RRB- and_CC blue_JJ and_CC orange_JJ signals_NNS on_IN the_DT der_NNP (_-LRB- 12_CD )_-RRB- )_-RRB- ._.
The_DT DAPI_NNP counterstaining_NN of_IN the_DT chromosomes_NNS has_VBZ been_VBN converted_VBN into_IN grey_JJ scale_NN to_TO simulate_VB a_DT G_NN -_HYPH banding_NN pattern_NN (_-LRB- figure_NN taken_VBN from_IN Naiel_NNP et_FW al._FW ,_, 2013_CD [_-LRB- 17_CD ]_-RRB- )_-RRB- ._.
b_NNP Schematic_JJ representation_NN showing_VBG localisation_NN and_CC colour_NN -_HYPH code_NN of_IN the_DT FISH_NN probes_NNS relative_RB to_IN the_DT three_CD colour_NN probe_NN set_NN used_VBN ._.
c_NNP FISH_NNP using_VBG a_DT two_CD colour_NN approach_NN enables_VBZ the_DT detection_NN of_IN both_CC normal_JJ chromosomes_NNS 7_CD (_-LRB- harbouring_VBG only_RB orange_JJ hybridisation_NN signals_NNS )_-RRB- and_CC 12_CD (_-LRB- harbouring_VBG only_RB green_JJ fluorescent_JJ signals_NNS )_-RRB- and_CC their_PRP$ derivatives_NNS carrying_VBG orange_JJ and_CC green_JJ fusion_NN signals_NNS ._.
d_NNP Schematic_JJ representation_NN showing_VBG localisation_NN and_CC colour_NN -_HYPH code_NN of_IN the_DT FISH_NN probes_NNS relative_RB to_IN the_DT two_CD colour_NN probe_NN set_NN used_VBN ._.
It_PRP should_MD be_VB noted_VBN that_IN the_DT two_CD colour_NN set_NN does_VBZ not_RB allow_VB to_TO discriminate_VB between_IN the_DT two_CD derivatives_NNS based_VBN on_IN colour_NN pattern_NN only_RB ._.
The_DT size_NN and_CC morphology_NN of_IN chromosomes_NNS 7_CD and_CC 12_CD compared_VBN to_IN their_PRP$ respective_JJ derivatives_NNS are_VBP very_RB similar_JJ ,_, making_VBG the_DT identification_NN of_IN the_DT rearrangement_NN difficult_JJ without_IN the_DT aid_NN of_IN FISH_NN ._.
Both_DT probe_NN sets_NNS have_VBP been_VBN provided_VBN by_IN MetaSystems_NNPS Gmbh_NNP ,_, Altlussheim_NNP ,_, Germany_NNP Dual_NNP colour_NN whole_JJ or_CC partial_JJ chromosome_NN painting_NN may_MD also_RB reveal_VB the_DT t(_NN 7;12_CD )_-RRB- (_-LRB- q36;p13_NN )_-RRB- ._.
However_RB ,_, visualisation_NN of_IN the_DT rearrangement_NN on_IN one_CD or_CC both_DT derivatives_NNS might_MD be_VB impaired_VBN due_IN to_IN the_DT small_JJ size_NN of_IN the_DT translocated_VBN fragments_NNS ._.
Reverse_JJ transcription_NN polymerase_NN chain_NN reaction_NN Specific_JJ primers_NNS have_VBP been_VBN designed_VBN for_IN the_DT detection_NN of_IN the_DT HLXB9_NNP /_SYM ETV6_NNP fusion_NN at_IN the_DT cDNA_NN level_NN by_IN reverse_NN transcription_NN polymerase_NN chain_NN reaction_NN (_-LRB- RT_NNP -_HYPH PCR_NNP )_-RRB- [_-LRB- 21_CD ]_-RRB- ._.
However_RB ,_, the_DT presence_NN of_IN a_DT fusion_NN transcript_NN by_IN RT_NNP -_HYPH PCR_NNP has_VBZ been_VBN identified_VBN only_RB in_IN approximately_RB 50_CD %_NN of_IN t(_SYM 7,12_CD )_-RRB- leukaemia_NN patients_NNS (_-LRB- Table_NNP 1_CD )_-RRB- ._.
For_IN this_DT reason_NN RT_NNP -_HYPH PCR_NNP does_VBZ not_RB represent_VB a_DT reliable_JJ method_NN for_IN the_DT detection_NN of_IN the_DT t(_$ 7;12_CD )_-RRB- rearrangements_NNS at_IN diagnosis_NN ._.
However_RB ,_, in_IN those_DT patients_NNS positive_JJ for_IN the_DT HLXB9_NNP /_SYM ETV6_NNP fusion_NN transcript_NN ,_, RT_NNP -_HYPH PCR_NNP would_MD prove_VB useful_JJ for_IN the_DT monitoring_NN of_IN minimal_JJ residual_JJ disease_NN [_-LRB- 53_CD ]_-RRB- ._.
Expression_NN profiling_NN Studies_NNPS based_VBN on_IN expression_NN microarrays_NNS have_VBP shown_VBN that_IN the_DT leukaemic_JJ cells_NNS of_IN patients_NNS carrying_VBG the_DT t(_$ 7;12_CD )_-RRB- have_VBP a_DT distinctive_JJ expression_NN pattern_NN that_WDT allows_VBZ to_TO discriminate_VB Table_NN 2_CD Summary_NN of_IN reports_NNS of_IN t(_$ 7;12_CD )_-RRB- leukaemias_NNS with_IN treatments_NNS and_CC clinical_JJ outcome_NN Reference_NN Study_NN group_NN
No._NN of_IN patients_NNS
CNS_NNP status_NN
Treatment_NN /_, Course_NN /_, Outcome_NN
[_-LRB- 15_LS ]_-RRB- DCLSG_NNP /_, POG_NNP 10_CD 5_CD Treatment_NNP N/S_NNP 6_CD died_VBD of_IN leukemia_NN 1_CD died_VBD of_IN leukemia_NN and_CC infection_NN 1_CD died_VBD of_IN infection_NN 1_CD died_VBD of_IN treatment_NN related_JJ toxicity_NN 1_CD alive_JJ ,_, 22_CD months_NNS after_IN BMT_NNP in_IN CR1_NNP
[_-LRB- 13_CD ]_-RRB- CCG_NNP 2_CD 2_CD 1_CD relapsed_VBN in_IN bone_NN marrow_NN with_IN bilateral_JJ chloromas_NNS on_IN the_DT hips_NNS ._.
Treated_VBN with_IN radiation_NN and_CC BMT_NNP ,_, but_CC later_RBR died_VBD due_IN to_IN disease_NN 1_CD relapsed_VBN twice_RB ,_, treated_VBN with_IN BMT_NNP ,_, alive_JJ after_IN 2_CD years_NNS
[_-LRB- 6_CD ]_-RRB- DCOG_NNP 6_CD N/S_NNP Treatment_NNP N/S_NNP Median_NNP EFS_NNP :_: 9_CD months_NNS 3_CD -_HYPH year_NN EFS_NN :_: 0_CD %_NN
3_CD -_HYPH year_NN OS_NN :_: 0_CD %_NN
[_-LRB- 19_CD ]_-RRB- Japan_NNP 1_CD N/S_NNP Alive_JJ after_IN 5_CD years_NNS ,_, treated_VBN with_IN chemotherapy_NN only_RB
[_-LRB- 16_CD ]_-RRB- Korea_NNP 3_CD N/S_NNP 1_CD received_VBD cord_NN blood_NN transplantation_NN at_IN 11_CD months_NNS ,_, relapsed_VBD 4_CD months_NNS later_RBR ,_, then_RB died_VBD at_IN 16_CD months_NNS 1_CD died_VBD during_IN induction_NN chemotherapy_NN from_IN multiple_JJ organ_NN failure_NN 1_CD achieved_VBD remission_NN ,_, but_CC relapsed_VBD at_IN 10_CD months_NNS ,_, and_CC died_VBD at_IN 16_CD months_NNS
[_-LRB- 56_LS ]_-RRB- COG_NN 8_CD N/S_NNP Treatment_NN N/S_NN 3_CD -_HYPH year_NN EFS_NN :_: 14_CD %_NN
3_CD -_HYPH year_NN OS_NN :_: 28_CD %_NN
2_CD of_IN 7_CD evaluable_JJ patients_NNS are_VBP alive_JJ (_-LRB- 1_CD after_IN chemotherapy_NN ,_, 1_CD after_IN BMT_NNP )_-RRB- (_-LRB- personal_JJ communication_NN )_-RRB-
Notes_NNS :_: DCLSG_NNP Dutch_NNP Childhood_NNP Leukemia_NNP Study_NNP Group_NNP ;_: POG_NNP Pediatric_NNP Oncology_NNP Group_NNP ;_: CCG_NNP Children_NNP 's_POS Cancer_NNP Group_NNP ;_: COG_NNP Children_NNP Oncology_NNP Group_NNP ;_: DCOG_NNP Dutch_NNP Childhood_NNP Oncology_NNP Group_NNP ;_: N/S_NNP not_RB specified_VBN ;_: BMT_NNP bone_NN marrow_NN transplantation_NN ;_: CR1_NNP first_JJ complete_JJ remission_NN ;_: EFS_NNP event_NN -_HYPH free_JJ survival_NN ;_: OS_NNP overall_JJ survival_NN Tosi_NNP et_FW al_NNP ._.
Biomarker_NNP Research_NNP (_-LRB- 2015_CD )_-RRB- 3:21_CD Page_NN 8_CD of_IN 11_CD this_DT specific_JJ cytogenetic_JJ subgroup_NN from_IN other_JJ [_-LRB- 51_CD ]_-RRB- ._.
Microarray_NN based_VBN technologies_NNS combined_VBN with_IN appropriate_JJ classifiers_NNS constitute_VBP potentially_RB a_DT very_RB powerful_JJ diagnostic_JJ approach_NN ,_, although_IN in_IN a_DT routine_JJ diagnostic_JJ laboratory_NN the_DT availability_NN of_IN specialised_VBN equipment_NN and_CC costs_NNS involved_VBN might_MD impact_VB on_IN the_DT choice_NN of_IN method_NN ._.
Incidence_NN A_DT literature_NN search_NN has_VBZ shown_VBN that_IN at_IN least_JJS 47_CD leukaemia_NN patients_NNS with_IN the_DT t(_NN 7;12_CD )_-RRB- have_VBP been_VBN reported_VBN to_IN date_NN ,_, based_VBN on_IN the_DT presence_NN of_IN the_DT chromosomal_JJ translocation_NN and_CC /_SYM or_CC the_DT fusion_NN transcript_NN [_-LRB- 17_CD ]_-RRB- ._.
To_IN date_NN ,_, there_EX are_VBP a_DT very_RB limited_JJ number_NN of_IN studies_NNS to_TO address_VB the_DT incidence_NN of_IN this_DT translocation_NN ,_, with_IN a_DT quite_RB comprehensive_JJ investigation_NN considering_VBG a_DT total_NN of_IN 345_CD paediatric_JJ patients_NNS [_-LRB- 6_CD ]_-RRB- ._.
In_IN this_DT study_NN ,_, patients_NNS were_VBD subdivided_VBN in_IN 289_CD ALL_DT ,_, of_IN which_WDT 99_CD were_VBD infants_NNS ,_, and_CC 59_CD AML_NNS ,_, of_IN which_WDT 18_CD were_VBD infants_NNS ._.
It_PRP emerged_VBD that_IN 5_CD out_IN of_IN 18_CD infant_NN AMLs_NNP (_-LRB- age_NN 0_CD -_SYM 12_CD months_NNS )_-RRB- harboured_VBD the_DT t(_$ 7;12_CD )_-RRB- rearrangement_NN ,_, making_VBG the_DT incidence_NN of_IN this_DT rearrangement_NN near_IN one_CD third_NN of_IN infant_NN AML_NN ._.
In_IN addition_NN to_IN the_DT above_NN ,_, the_DT t(_NN 7;12_CD )_-RRB- was_VBD also_RB found_VBN in_IN one_CD infant_NN with_IN ALL_DT and_CC one_CD 18_CD month_NN old_JJ child_NN with_IN AML_NNP ._.
A_DT previous_JJ study_NN was_VBD conducted_VBN on_IN a_DT more_RBR selected_VBN series_NN of_IN leukaemia_NN patients_NNS ,_, chosen_VBN on_IN the_DT basis_NN of_IN age_NN <_-LRB- 20_CD months_NNS and_CC the_DT presence_NN of_IN additional_JJ copies_NNS of_IN chromosomes_NNS 8_CD and_CC /_, or_CC 19_CD ,_, as_RB well_RB as_IN abnormalities_NNS of_IN 7q_NN and_CC /_, or_CC 12_CD p_NN [_-LRB- 7_CD ]_-RRB- ._.
This_DT study_NN showed_VBD that_IN 10_CD out_IN of_IN 23_CD patients_NNS harboured_VBD a_DT translocation_NN between_IN 7q_CD and_CC 12_CD p_NN ._.
However_RB ,_, in_IN only_RB 7_CD cases_NNS ETV6_NNP was_VBD involved_VBN in_IN the_DT translocation_NN and_CC of_IN these_DT ,_, 6_CD cases_NNS had_VBD breakpoint_NN in_IN 7q36_CD and_CC one_CD in_IN 7q22_CD ._.
Later_JJR studies_NNS confirmed_VBD that_IN the_DT incidence_NN of_IN t(_NNP 7;12_CD )_-RRB- (_-LRB- q36;p13_NN )_-RRB- was_VBD low_JJ when_WRB considering_VBG AML_NNP paediatric_JJ patients_NNS enrolled_VBN for_IN clinical_JJ trials_NNS ._.
These_DT studies_NNS reported_VBD four_CD t(_SYM 7;12_CD )_-RRB- cases_NNS out_IN of_IN 729_CD enrolled_VBN in_IN the_DT UK_NNP MRC_NNP AML10_NNP and_CC AML_NNP 12_CD ;_: one_CD case_NN out_IN of_IN 454_CD in_IN AML_NNP -_HYPH BFM_NNP 98_CD and_CC 8_CD cases_NNS out_IN of_IN 981_CD enrolled_VBN in_IN the_DT COG_NNP trial_NN AAML0531_NNP [_-LRB- 54_CD -_SYM 56_CD ]_-RRB- ._.
Prognostic_JJ significance_NN and_CC treatment_NN options_NNS Prognostic_JJ significance_NN and_CC clinical_JJ outcome_NN Cytogenetic_JJ and_CC molecular_JJ markers_NNS are_VBP important_JJ factors_NNS to_TO be_VB taken_VBN in_IN consideration_NN when_WRB stratifying_VBG patients_NNS into_IN high_JJ risk_NN /_, low_JJ risk_NN categories_NNS and_CC are_VBP of_IN guidance_NN for_IN making_VBG treatment_NN choices_NNS ._.
The_DT WHO_WDT system_NN for_IN the_DT classification_NN of_IN myeloid_NN neoplasms_NNS and_CC acute_JJ leukemia_NN has_VBZ been_VBN amended_VBN to_TO include_VB such_JJ information_NN [_-LRB- 5_CD ]_-RRB- ._.
At_IN present_JJ ,_, the_DT t(_NN 7;12_CD )_-RRB- (_-LRB- q36;p13_NN )_-RRB- is_VBZ not_RB included_VBN in_IN the_DT WHO_WDT classification_NN ,_, although_IN it_PRP is_VBZ recommended_VBN that_IN it_PRP be_VB considered_VBN as_IN a_DT separate_JJ entity_NN when_WRB assessing_VBG infant_NN leukaemia_NN [_-LRB- 3_CD ]_-RRB- ._.
Review_NN of_IN published_VBN data_NNS on_IN the_DT clinical_JJ outcome_NN of_IN the_DT t(_NN 7;12_CD )_-RRB- AMLs_NNP reveals_VBZ inferior_JJ outcome_NN with_IN 3_CD years_NNS probabilities_NNS of_IN event_NN free_JJ survival_NN (_-LRB- EFS_NNP )_-RRB- of_IN 0_CD -_SYM 14_CD %_NN and_CC overall_JJ survival_NN (_-LRB- OS_NNP )_-RRB- of_IN 0_CD -_SYM 28_CD %_NN (_-LRB- Table_NNP 2_CD )_-RRB- [_-LRB- 6_CD ,_, 13_CD ,_, 14_CD ,_, 16_CD ,_, 56_CD ]_-RRB- ._.
However_RB ,_, one_CD report_NN of_IN a_DT paediatric_JJ patient_NN with_IN acute_JJ megakaryocytic_JJ leukaemia_NN and_CC t(_SYM 7;12_CD )_-RRB- described_VBD achievement_NN of_IN complete_JJ remission_NN with_IN chemotherapy_NN alone_RB for_IN 60_CD months_NNS at_IN time_NN of_IN publication_NN [_-LRB- 19_CD ]_-RRB- ._.
Papers_NNS from_IN different_JJ clinical_JJ trial_NN groups_NNS such_JJ as_IN the_DT Children_NNPS 's_POS Oncology_NNP Group_NNP (_-LRB- COG_NNP )_-RRB- [_-LRB- 56_CD ]_-RRB- ,_, UK_NNP MRC_NNP AML_NNP 10_CD and_CC 12_CD [_-LRB- 53_CD ]_-RRB- and_CC the_DT Berlin_NNP -_HYPH Frankfurt_NNP -_HYPH Munich_NNP (_-LRB- BFM_NNP )_-RRB- [_-LRB- 55_CD ]_-RRB- included_VBD the_DT t(_NN 7;12_CD )_-RRB- (_-LRB- q36;p13_NN )_-RRB- in_IN the_DT group_NN of_IN patients_NNS with_IN 12_CD p_NN abnormalities_NNS and_CC confirmed_VBD their_PRP$ association_NN with_IN poor_JJ prognosis_NN ._.
It_PRP was_VBD also_RB stressed_VBN the_DT need_NN to_IN Tosi_NNP et_NNP al_NNP ._.
Biomarker_NNP Research_NNP (_-LRB- 2015_CD )_-RRB- 3:21_CD Page_NN 9_CD of_IN 11_CD consider_VBP these_DT patients_NNS as_IN a_DT high_JJ risk_NN group_NN based_VBN on_IN the_DT cytogenetic_JJ classification_NN of_IN AML_NN ._.
Standard_JJ treatment_NN Standard_NNP treatment_NN for_IN paediatric_JJ patients_NNS with_IN AML_NNP includes_VBZ induction_NN chemotherapy_NN (_-LRB- remission_NN induction_NN )_-RRB- with_IN an_DT anthracycline_NN based_VBN regimen_NN which_WDT also_RB contains_VBZ cytarabine_NN ._.
The_DT choice_NN of_IN the_DT anthracycline_NN drug_NN used_VBN ,_, as_RB well_RB as_IN the_DT total_JJ doses_NNS of_IN chemotherapy_NN differ_VBP between_IN different_JJ centres_NNS and_CC collaborative_JJ study_NN groups_NNS ._.
Most_JJS children_NNS achieve_VBP complete_JJ remission_NN with_IN rates_NNS of_IN 80_CD -_SYM 90_CD %_NN after_IN 2_CD induction_NN courses_NNS and_CC the_DT toxic_JJ death_NN rate_NN is_VBZ in_IN the_DT region_NN of_IN 5_CD %_NN ,_, with_IN the_DT failures_NNS being_VBG due_IN to_IN resistant_JJ disease_NN [_-LRB- 4_CD ]_-RRB- ._.
Consolidation_NN or_CC Intensification_NN chemotherapy_NN (_-LRB- post_NN -_HYPH remission_NN therapy_NN )_-RRB- is_VBZ essential_JJ for_IN cure_NN ._.
It_PRP includes_VBZ the_DT administration_NN of_IN high_JJ dose_NN cytarabine_NN possibly_RB in_IN combination_NN with_IN other_JJ drugs_NNS ._.
Doses_NNS ,_, duration_NN ,_, number_NN of_IN drugs_NNS as_RB well_RB as_IN scheduling_NN differ_VBP between_IN collaborative_JJ groups_NNS ._.
Currently_RB ,_, treatment_NN related_JJ death_NN rates_NNS in_IN AML_NNP paediatric_JJ patients_NNS ,_, with_IN the_DT improvement_NN of_IN supportive_JJ care_NN and_CC the_DT administration_NN of_IN treatment_NN in_IN experienced_VBN units_NNS ,_, are_VBP now_RB less_JJR than_IN 10_CD %_NN [_-LRB- 4_CD ]_-RRB- ._.
Stem_NN cell_NN transplantation_NN Haematopoietic_JJ stem_NN cell_NN transplantation_NN (_-LRB- HSCT_NN )_-RRB- is_VBZ considered_VBN an_DT effective_JJ therapy_NN for_IN treatment_NN of_IN high_JJ risk_NN leukaemia_NN ._.
However_RB ,_, the_DT high_JJ toxicity_NN which_WDT includes_VBZ a_DT mortality_NN rate_NN reaching_VBG up_RP to_IN 20_CD %_NN in_IN some_DT series_NN ,_, makes_VBZ it_PRP not_RB a_DT standard_JJ therapy_NN in_IN the_DT first_JJ line_NN treatment_NN of_IN AML_NN patients_NNS with_IN favourable_JJ cytogenetics_NNS ,_, where_WRB a_DT high_JJ cure_NN rate_NN is_VBZ achieved_VBN with_IN chemotherapy_NN alone_RB ._.
For_IN patients_NNS with_IN unfavourable_JJ cytogenetics_NNS ,_, although_IN the_DT benefit_NN of_IN HSCT_NNP is_VBZ still_RB to_TO be_VB fully_RB explored_VBN ,_, HSCT_NNP is_VBZ considered_VBN by_IN many_JJ groups_NNS as_IN the_DT standard_NN of_IN care_NN [_-LRB- 57_CD ,_, 58_CD ]_-RRB- ._.
When_WRB patients_NNS relapse_VBP ,_, the_DT most_RBS important_JJ prognostic_JJ factors_NNS that_WDT will_MD determine_VB the_DT outcome_NN of_IN the_DT salvage_NN therapy_NN are_VBP the_DT length_NN of_IN first_JJ remission_NN and_CC cytogenetics_NNS ._.
In_IN the_DT United_NNP Kingdom_NNP ,_, HSCT_NNP is_VBZ generally_RB used_VBN as_IN consolidation_NN therapy_NN as_IN part_NN of_IN salvage_NN treatment_NN with_IN a_DT survival_NN rate_NN of_IN around_RB 40_CD %_NN achieved_VBN irrespective_JJ of_IN the_DT source_NN of_IN stem_NN cells_NNS ._.
However_RB ,_, it_PRP is_VBZ important_JJ to_TO better_RBR understand_VB molecular_NN markers_NNS and_CC cytogenetics_NNS of_IN the_DT disease_NN to_TO identify_VB patients_NNS who_WP would_MD most_RBS likely_RB benefit_VB from_IN this_DT modality_NN of_IN treatment_NN [_-LRB- 59_CD ]_-RRB- ._.
To_IN date_NN ,_, although_IN there_EX are_VBP no_DT published_VBN guidelines_NNS about_IN the_DT management_NN of_IN this_DT group_NN ,_, there_EX is_VBZ increasing_VBG interest_NN among_IN paediatric_JJ haematologists_NNS /_, study_NN groups_NNS to_TO consider_VB intensification_NN of_IN therapy_NN with_IN allogeneic_JJ stem_NN cell_NN transplantation_NN in_IN first_JJ complete_JJ remission_NN [_-LRB- 13_CD ,_, 15_CD ,_, 16_CD ,_, 56_CD ]_-RRB- ._.
Further_JJR study_NN of_IN this_DT important_JJ subgroup_NN of_IN infant_NN AML_NN as_RB well_RB as_IN the_DT incorporation_NN of_IN t(_$ 7;12_CD )_-RRB- in_IN future_JJ risk_NN stratification_NN schemas_NNS are_VBP needed_VBN to_TO better_RBR understand_VB the_DT best_JJS treatment_NN approach_NN ._.
Conclusions_NNS The_DT t(_NN 7;12_CD )_-RRB- (_-LRB- q36;p13_NN )_-RRB- is_VBZ a_DT rare_JJ cytogenetic_JJ abnormality_NN in_IN paediatric_JJ AML_NN and_CC difficult_JJ to_TO identify_VB using_VBG conventional_JJ karyotyping_NN ._.
The_DT use_NN of_IN FISH_NN with_IN appropriate_JJ probe_NN sets_NNS would_MD enable_VB diagnostic_JJ laboratories_NNS to_TO identify_VB this_DT cytogenetic_JJ entity_NN confidently_RB and_CC to_TO give_VB a_DT better_JJR estimate_NN of_IN its_PRP$ occurrence_NN ._.
The_DT incidence_NN of_IN t(_$ 7;12_CD )_-RRB- leukaemias_NNS is_VBZ low_JJ in_IN overall_JJ paediatric_JJ AML_NN ,_, but_CC significant_JJ in_IN infant_NN leukaemia_NN ._.
There_EX are_VBP no_DT published_VBN management_NN guidelines_NNS for_IN those_DT patients_NNS ,_, but_CC it_PRP is_VBZ now_RB acknowledged_VBN as_IN a_DT high_JJ risk_NN group_NN with_IN poor_JJ prognosis_NN and_CC accordingly_RB many_JJ are_VBP being_VBG treated_VBN with_IN HSCT_NNP in_IN first_JJ complete_JJ remission_NN ._.
Better_JJR understanding_NN of_IN the_DT genetic_JJ mechanisms_NNS at_IN the_DT basis_NN of_IN t(_$ 7;12_CD )_-RRB- leukaemias_NNS and_CC the_DT role_NN of_IN HLXB9_NN in_IN the_DT establishment_NN of_IN this_DT malignancies_NNS would_MD provide_VB grounds_NNS for_IN possible_JJ tailored_VBN therapy_NN ._.